CASI casipharmaceuticals.com Final Profit

CASI (casipharmaceuticals.com) - company brandmark

High barriers to entry due to patent protection and stringent FDA/NMPA oversight are amplified by geopolitical pressure between the US and China, which limits the recognition of research. The financial performance of CASI Pharmaceuticals (CASI) visualizes these complexities, where the value of 0.00 corresponds to the current metric. However, the commercialization of approved drugs in China creates a steady cash flow, ensuring a positive growth outlook.

CASI (CASI Pharmaceuticals Inc.) Net Profit history from 07/04/2022 to 03/14/2026

Analytical breakdowns and data insights for company casipharmaceuticals.com (CASI)

- stock value and consensus price forecast:
Market Price CASI Pharmaceuticals, Inc.|CASI - Price Target Chart
- market capitalization data:
Market Value CASI Pharmaceuticals, Inc|CASI - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share CASI Pharmaceuticals|CASI - Book Capitalization|Market Value to Book Value Ratio casipharmaceuticals.com|CASI - Aggregate Company Assets
- debt and solvency information:
Debt to Equity CASI Pharmaceuticals|CASI - Long-Term Debt to Equity|Current Liabilities to Capital CASI Pharmaceuticals, Inc.|CASI - Company Debts|Debts to Book Value CASI Pharmaceuticals, Inc|CASI - Company Long-Term Debts|Company Short-Term Indebtedness CASI Pharmaceuticals|Quick Liquidity Indicator casipharmaceuticals.com
- net income and valuation multiples indicators:
CASI - Net Profit
Basic company analysis:CASI CASI Pharmaceuticals, Inc
Finished products of CASI Pharmaceuticals

This indicator aggregates the organization's daily financial results, allowing investors to assess cash flow stability and avoid purchasing the asset at local peaks. The profit trend for CASI Pharmaceuticals reflects the efficiency of its oncology drug expansion in China and the success of its B2B licensing, confirming the company's ability to scale its business within the blood cancer therapy segment.

Direct competitors

Company Net Income TG Pharma (TGTX)|Company Net Income Arcellx|IRON: Final Profit|Net Income SNDX (Syndax Pharmaceuticals, Inc.)|KURA (Kura Oncology Inc) - Final Profit|Net Profit ADCT (ADC Therapeutics Corp)|Foghorn Therapeutics, Inc. - Company Net Income|VOR - Company Net Income|NKTX: Company Net Income|coeptistx.com (COEP) - Company Net Income|Company Net Income Actinium Pharma (ATNM)|Company Net Income Estrella Bio|Company Net Income Marker Bio MRKR|Net Profit INAB|eternatx.com - Company Profit|Net Profit GTBP (GT Biopharma)|APTO - Net Income|Bio-Path - Net Profit|MEIP - Net Profit|vincerx.com (VINC) - Company Net Income